Novel small molecule inhibitors of oncogenic SHP2 variants characterised by cellular target engagement
Lester J. Lambert, PhD, Research Scientist, Nicholas Cosford Laboratory, Sanford Burnham Prebys Medical Discovery Institute
Lester Lambert obtained his PhD from the University of Notre Dame in biochemistry and chemical biology. He pursued postdoctoral work in structural biology at the Rockefeller University and the Burnham Institute. His current focus is the discovery of small molecule modulators of cell signalling in cancer, neurodegenerative diseases and infection.
Paul Shapiro, PhD, Group Leader, Assay and Product Development, Research and Development Department, Eurofins DiscoverX
Paul Shapiro obtained his PhD from the University of California, San Diego in pharmacology and physiology. He has more than 15 years of industry experience in assay development for drug discovery and pharmacology, across multiple therapeutic areas and target classes.
Related topics
Assays, Biopharmaceuticals, Cell-based assays, Clinical Trials, Drug Development, Drug Discovery, Hit-to-Lead, In Vitro, Kinases, Screening, Small molecule, Small Molecules, Targets, Technology
Related organisations
Eurofins DiscoverX, Eurofins Discovery, Sanford Burnham Prebys Discovery
